Compare MED & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MED | IPHA |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.0M | 189.5M |
| IPO Year | 1996 | N/A |
| Metric | MED | IPHA |
|---|---|---|
| Price | $12.18 | $1.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $5.75 |
| AVG Volume (30 Days) | ★ 154.9K | 135.0K |
| Earning Date | 05-04-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $934,842,000.00 | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.22 | $1.18 |
| 52 Week High | $15.37 | $2.63 |
| Indicator | MED | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 51.54 |
| Support Level | $10.10 | $1.69 |
| Resistance Level | $12.21 | $1.84 |
| Average True Range (ATR) | 0.45 | 0.13 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 4.78 | 9.90 |
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.